Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Deputy Commissioner Friedman To Join Searle As Senior VP-Clinical

Executive Summary

FDA Deputy Commissioner for Operations Michael Friedman, MD, is leaving the agency to join Searle as senior VP-clinical affairs.

You may also be interested in...



Searle Oncology Given Boost By Pending P&U Merger, Antibody Deal

Searle will create a platform for new oncologics development through a research collaboration with Cambridge Antibody Technology.

Searle Oncology Given Boost By Pending P&U Merger, Antibody Deal

Searle will create a platform for new oncologics development through a research collaboration with Cambridge Antibody Technology.

FDA Senior Scientist Schwetz To Chair Deputy Commissioner Search Cmte.

FDA Senior Advisor for Science Bernard Schwetz, PhD, will serve as acting deputy commissioner as the agency searches for a permanent deputy for the position recently vacated by Michael Friedman, MD.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS034358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel